Optinose | 10-Q: FY2025 Q1 Revenue Beats Estimate at USD 18.51 M

Revenue: As of FY2025 Q1, the actual value is USD 18.51 M, beating the estimate of USD 17.7 M.

EPS: As of FY2025 Q1, the actual value is USD -1.92.

Segment Revenue

• Net Product Revenues: OptiNose, Inc. reported net product revenues of $18.5 million for the three months ended March 31, 2025, compared to $14.9 million for the same period in 2024, reflecting a year-over-year increase primarily due to the chronic sinusitis launch and favorable pricing and business mix.

Operational Metrics

• Net Loss: The company reported a net loss of $22.4 million for the three months ended March 31, 2025, compared to a net loss of $14.1 million for the same period in 2024.
• Loss from Operations: Loss from operations was $7.6 million for the three months ended March 31, 2025, compared to $8.1 million for the same period in 2024.
• Selling, General and Administrative Expenses: These expenses increased to $23.6 million for the three months ended March 31, 2025, from $20.5 million in the same period in 2024, primarily due to increased sales and marketing costs related to the launch of XHANCE for chronic sinusitis and increased legal and financial advisory fees related to the Merger Agreement.

Cash Flow

• Cash Used in Operating Activities: Cash used in operating activities was $11.6 million for the three months ended March 31, 2025, compared to $22.0 million for the same period in 2024, reflecting a decrease primarily attributable to changes in accounts payable and accrued expenses.

Unique Metrics

• XHANCE Prescriptions: The total estimated number of XHANCE prescriptions in the first quarter of 2025 was 71,300, representing a 9% increase compared to the first quarter of 2024.

Future Outlook and Strategy

• Core Business Focus: OptiNose plans to continue focusing its commercial efforts primarily on the ENT and allergy specialist audience while seeking partnerships to extend the commercialization of XHANCE into primary care. The company is relaunching XHANCE to focus on the larger market opportunity created by the new indication for chronic sinusitis.
• Non-Core Business: The company entered into a Merger Agreement with Paratek Pharmaceuticals, Inc., which is expected to be consummated on or around May 21, 2025, subject to stockholder approval and other closing conditions.